• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌转移中 Ga-PSMA PET/CT 表现酷似脊柱骨髓瘤。

Vertebral Myeloma Mimicking Prostatic Carcinoma Metastasis in 68Ga-PSMA PET/CT.

机构信息

From the Departments of *Oncology, †Pathology, and ‡Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark.

出版信息

Clin Nucl Med. 2017 Oct;42(10):790-792. doi: 10.1097/RLU.0000000000001773.

DOI:10.1097/RLU.0000000000001773
PMID:28737577
Abstract

Ga-PSMA PET/CT was performed in a 75-year-old man with newly diagnosed prostate cancer because of an equivocal lesion in the spine both on Tc-bone-SPECT/CT and MRI. Because of increased PSMA activity on PET/CT, the bone lesion was interpreted as metastasis from prostate cancer. Later, the patient was diagnosed as having monoclonal gammopathy of unknown significance. A biopsy was performed, and histological examination revealed multiple myeloma with PSMA expression in the neovessels but no metastatic prostate cancer cells. The patient was downstaged, and the treatment was changed accordingly. This case illustrates the importance of biopsies from PSMA PET-positive lesions.

摘要

Ga-PSMA PET/CT 检查在一名 75 岁男性中进行,该男性新诊断为前列腺癌,原因是 Tc-骨 SPECT/CT 和 MRI 上脊柱的可疑病变。由于 PET/CT 上 PSMA 活性增加,骨病变被解释为前列腺癌转移。后来,该患者被诊断为意义未明的单克隆丙种球蛋白病。进行了活检,组织学检查显示多发性骨髓瘤,新血管中有 PSMA 表达,但没有转移性前列腺癌细胞。患者降期,治疗相应改变。本病例说明了对 PSMA PET 阳性病变进行活检的重要性。

相似文献

1
Vertebral Myeloma Mimicking Prostatic Carcinoma Metastasis in 68Ga-PSMA PET/CT.前列腺癌转移中 Ga-PSMA PET/CT 表现酷似脊柱骨髓瘤。
Clin Nucl Med. 2017 Oct;42(10):790-792. doi: 10.1097/RLU.0000000000001773.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.68Ga-PSMA-11 PET/CT 衍生的定量肿瘤体积参数可用于前列腺癌骨转移患者的分类和治疗反应评估。
Ann Nucl Med. 2019 Oct;33(10):766-775. doi: 10.1007/s12149-019-01387-0. Epub 2019 Jul 23.
4
Extraosseous Extension of Aggressive Vertebral Hemangioma as a Potential Pitfall on 68Ga-PSMA PET/CT.椎体侵袭性血管瘤骨外延伸:68Ga-PSMA PET/CT 潜在的陷阱
Clin Nucl Med. 2017 Aug;42(8):624-625. doi: 10.1097/RLU.0000000000001731.
5
Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli?镓-PSMA PET/CT 取代骨扫描在前列腺癌骨转移初始分期中的应用:已成定局?
Clin Genitourin Cancer. 2018 Oct;16(5):392-401. doi: 10.1016/j.clgc.2018.07.009. Epub 2018 Jul 21.
6
Multiple Solitary Plasmacytomas With Multifocal Bone Involvement Diagnosed With 68Ga-Prostate-Specific Membrane Antigen PET/CT.68Ga-前列腺特异性膜抗原 PET/CT 诊断多发性孤立性浆细胞瘤伴多灶性骨累及。
Clin Nucl Med. 2020 Jan;45(1):e51-e52. doi: 10.1097/RLU.0000000000002682.
7
68Ga-PSMA PET/CT Imaging in Multiple Myeloma.68Ga-PSMA PET/CT 成像在多发性骨髓瘤中的应用。
Clin Nucl Med. 2017 Feb;42(2):e126-e127. doi: 10.1097/RLU.0000000000001479.
8
Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.前列腺癌确定性放射治疗前的镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描分期
Asia Pac J Clin Oncol. 2018 Aug;14(4):343-346. doi: 10.1111/ajco.12872. Epub 2018 Apr 16.
9
Factors Predicting Metastatic Disease in Ga-PSMA-11 PET-Positive Osseous Lesions in Prostate Cancer.预测前列腺癌 Ga-PSMA-11 PET 阳性骨病变转移疾病的因素。
J Nucl Med. 2020 Dec;61(12):1779-1785. doi: 10.2967/jnumed.119.241174. Epub 2020 Apr 17.
10
68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.68Ga-PSMA-11 PET/CT 在前列腺腺癌新诊断中的应用。
Clin Nucl Med. 2018 Dec;43(12):e422-e427. doi: 10.1097/RLU.0000000000002289.

引用本文的文献

1
Characterization of exclusive rib lesions detected by [ 68 Ga]Ga-PSMA-11 PET/CT.[68Ga]镓-PSMA-11 PET/CT检测到的孤立肋骨病变的特征
Nucl Med Commun. 2025 Jan 1;46(1):95-105. doi: 10.1097/MNM.0000000000001919. Epub 2024 Dec 10.
2
Multiple myeloma with diffuse uptake on F-PSMA-1007 positron emission tomography/computed tomography: a case description and literature review.F-PSMA-1007正电子发射断层扫描/计算机断层扫描显示弥漫性摄取的多发性骨髓瘤:病例描述及文献综述
Quant Imaging Med Surg. 2023 Aug 1;13(8):5369-5373. doi: 10.21037/qims-22-1310. Epub 2023 Jun 8.
3
A look into the future: the role of PSMA beyond prostate cancer.
展望未来:前列腺特异性膜抗原在前列腺癌之外的作用。
Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):278-280. doi: 10.1007/s00259-023-06388-w.
4
Diagnostic value of machine learning-based computed tomography texture analysis for differentiating multiple myeloma from osteolytic metastatic bone lesions in the peripheral skeleton.基于机器学习的 CT 纹理分析对鉴别外周骨溶骨性转移病灶与多发性骨髓瘤的诊断价值。
Skeletal Radiol. 2023 Sep;52(9):1703-1711. doi: 10.1007/s00256-023-04333-4. Epub 2023 Apr 4.
5
Head-to-head comparison of [Ga]Ga-PSMA-11 and [F]FDG PET/CT in multiple myeloma.镓[68Ga]PSMA-11 与氟[18F]脱氧葡萄糖 PET/CT 对头对头比较多发性骨髓瘤。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2432-2440. doi: 10.1007/s00259-023-06214-3. Epub 2023 Mar 29.
6
Not All Glittering Bone Lesions Are Gold: A Case of Sclerotic Bone Lesions with Elevated Ga PSMA and Tc HDP Uptake with No Signs of Malignancy.并非所有闪烁的骨病变都是良性的:一例硬化性骨病变,伴有升高的镓 PSMA 和锝 HDP 摄取,无恶性迹象。
World J Nucl Med. 2022 Dec 20;22(1):67-69. doi: 10.1055/s-0042-1758805. eCollection 2023 Mar.
7
Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers.前列腺癌和非前列腺癌的镓-68 标记前列腺特异性膜抗原 11 PET/CT
AJR Am J Roentgenol. 2019 Aug;213(2):286-299. doi: 10.2214/AJR.19.21084. Epub 2019 Jun 5.
8
Morbidity and Mortality: A Case Report of Metastatic Bone Disease.发病率与死亡率:转移性骨病病例报告
Cureus. 2018 Dec 27;10(12):e3781. doi: 10.7759/cureus.3781.
9
Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma.伴有骨髓浸润、酷似多发性骨髓瘤的转移性前列腺癌。
Clin Case Rep. 2017 Dec 22;6(2):269-273. doi: 10.1002/ccr3.1308. eCollection 2018 Feb.